HomeFinancial MarketsApellis Pharmaceuticals Stock Surges Amid Takeover Rumors

Apellis Pharmaceuticals Stock Surges Amid Takeover Rumors

The shares of Apellis Pharmaceuticals surged on Monday after reports that the biotech company might be set for a takeover by one of the industry leaders. The Apellis stock jumped more than 16% at one point after the news got out.

Bloomberg reports that Apellis is drawing interest from several large pharma firms and is currently considering its options. The company has already contacted an advisor to help them through the process while also considering several other moves. One of them could be securing licensing agreements or partnerships.

Apellis Pharmaceuticals focuses on developing treatments for autoimmune and inflammatory diseases. The Waltham, Massachusetts, headquartered company recently secured FDA approval for its drug Syfovre, which is used for treating geographic atrophy and has the potential of generating revenue up to $1 billion, according to analyst estimates.

In the wake of takeover rumors, Wells Fargo analyst Derek Archila projected that the potential sale of Apellis could be valued north of $10 billion. Archila estimates that the sale could go through at the price of $90 to $100 per share.

After Monday’s jump, Apellis shares are already at their all-time high. The stock traded at around $76.38 per share, representing a 51.91% increase year-to-date.

Home Prices Rise for Second Straight Month

U.S. home prices increased for a second consecutive month in March, reflecting the sustained inventory shortage faced by buyers. This streak comes after seven...

Futures Rise as Debt Ceiling Deal Set for Next Challenge

U.S. futures advanced during Tuesday's morning session as investors wait for the U.S. debt-ceiling deal to be presented before Congress. Policymakers are under pressure...

Oil Remains Steady as Traders Await Approval of Debt Ceiling Deal

Oil remained little changed on Monday as traders wait to see if lawmakers approve the U.S. debt ceiling deal that policymakers agreed to on...